• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

还没做过化疗,EGFR是野生型的病友一定要去做ALK的检测

  [复制链接]
156850 162 godblessmymum 发表于 2012-6-16 23:11:32 |
健康活着  小学五年级 发表于 2012-9-18 18:53:34 | 显示全部楼层 来自: 广东广州
落花无意  小学六年级 发表于 2012-9-22 15:56:39 | 显示全部楼层 来自: 上海
请问,肺鳞癌,只做过一次化疗,骨髓抑制严重,后吃特罗凯4个月基本无效,可以参加实验组吗?
godblessmymum  大学二年级 发表于 2012-9-24 20:13:39 | 显示全部楼层 来自: 上海虹口区
不可以了,要没做过任何治疗的,包括化疗和靶向药
老马  博士一年级 发表于 2012-10-14 22:18:42 | 显示全部楼层 来自: 浙江温州
Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
. o  S7 _5 z$ B- w* {) K. D" V. _7 o. p  P7 t: p5 z
: X3 O3 k  U5 ~2 Z! c2 N3 \
Sub-category:
: r: n1 q0 G! a3 h* I1 \Molecular Targets
. g3 D/ O$ ]$ T8 t3 P* a5 z' @8 x* _" d* p+ F+ w
5 i8 f3 t  f7 P6 V
Category:
' `2 U. q3 f: Y5 R8 DTumor Biology ! k$ }  R- U* w$ U0 l

2 ~+ a/ U5 |# u# B0 Y. ?* u9 l" y; [. l# x
Meeting:- ]: F- d: @; @$ @3 Y4 y; G# [
2011 ASCO Annual Meeting
, A$ E  J) F" n) G6 Q+ b/ i6 g; X$ \  u, F9 W) a6 U0 K

1 u' ?0 H4 a: F) b1 v3 t" i* `; {Session Type and Session Title:
+ h/ I* _. W. Y( E$ {$ [Poster Discussion Session, Tumor Biology
0 m& |/ j: b, F+ r0 Y$ f0 G6 E8 `( f! k3 ^4 K3 L6 z, o
- [6 I6 @; M9 d4 C
Abstract No:
: Z0 O" r0 K, z$ q1 w10517 . \; q' [( H& W% K5 D0 u
4 ^+ v7 Y6 }- l" F- v$ B1 T. ]/ {

5 r2 N  \- h1 X* T4 q0 c9 ?Citation:
' ]! D# K( T+ u; {J Clin Oncol 29: 2011 (suppl; abstr 10517) 2 C. B8 Y9 n* B# ~, a

: v4 y1 N7 I# W7 J! g9 r# D. N* r( ?9 @. t/ x) O
Author(s):+ w" n! }1 ]8 q
J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China , S) o. _- W7 x' U4 x9 s+ t/ c/ `" C( m

5 F. Z7 w* ^$ T3 G% Y
* {! l. ~( @% X
7 O: ~3 O) Q5 P: [( F' qAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.7 L: G% Y4 A; F; [' B/ a# w

' q" o; M- v5 y9 H0 ~! FAbstract Disclosures0 G9 s$ t/ a0 A

- N( O" @5 {/ Q) Z' O0 M/ sAbstract:# k, c) E! t% J0 h' v

" W% p0 y: i* o: h: ]: F8 Z. d) q
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.
6 F4 l) M5 D: q* S2 g: n' n
# a" t8 v/ U; z) P$ s6 B" y
( s; d. k) A$ L- b# F
个人公众号:treeofhope
累计签到:8 天
连续签到:1 天
[LV.3]与爱熟人
一只白杨  大学一年级 发表于 2012-11-15 17:48:59 | 显示全部楼层 来自: 广东广州
由吴一龙教授牵头的A80810029临床试验上周启动,初诊未治疗的晚期肺腺癌患者检测到ALK阳性,可参加一线crizotinib 对比力比泰+卡铂的临床研究,药物全部免费,即使分配到力比泰组,疾病进展之后可免费获得crizotinib.
boeun  小学四年级 发表于 2012-11-18 16:37:21 | 显示全部楼层 来自: 福建泉州
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
godblessmymum  大学二年级 发表于 2012-11-18 23:23:21 | 显示全部楼层 来自: 上海杨浦区
boeun 发表于 2012-11-18 16:37 # P( b7 R5 E+ s, K
没有手术,只化疗过,现吃靶向药,未突变,alk未测,有机会入组吗?
. G2 C  c6 Q$ T+ N
化疗过的没机会了
helpU  高中三年级 发表于 2012-12-3 21:04:24 | 显示全部楼层 来自: 北京
平安! 发表于 2012-7-20 11:20
; ?0 a- a1 L3 v# d0 o( k: {易瑞沙、特罗凯有效的病人基本上可以断定ALK(-)。极其罕见EGFR、ALK同时突变的。) d! ^* I; ^9 _
ALK一个指标医院要900多 ...
6 g  ]1 F8 E4 @% Z5 b9 N
平安,真的没有希望吗?我弟弟虽然特罗凯有效,但是EGFR是野生型,不是突变啊。有没有必要去检测ALK呢?
; m. K8 f1 O7 }1 \
$ l6 Q, r4 k$ Y' U4 h$ q- F2 l现在病情进展,快没招儿了。
294170420  初中二年级 发表于 2012-12-4 22:04:38 | 显示全部楼层 来自: 浙江丽水
好像想加入挺困难的
wdc2482  小学六年级 发表于 2012-12-19 18:47:22 | 显示全部楼层 来自: 青海西宁
小地方没条件做啊

举报 使用道具

回复 支持 0 反对 1

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表